Affimed NV (NASDAQ:AFMD) has received a consensus rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $4.99.
Several brokerages have recently commented on AFMD. ValuEngine raised Affimed from a “hold” rating to a “buy” rating in a research note on Wednesday, March 20th. Zacks Investment Research raised Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 price objective for the company in a research note on Friday, March 29th. Svb Leerink began coverage on Affimed in a research note on Thursday, March 28th. They issued an “outperform” rating and a $8.00 price objective for the company. Finally, Leerink Swann began coverage on Affimed in a research note on Thursday, March 28th. They issued an “outperform” rating and a $4.17 price objective for the company.
Shares of Affimed stock traded up $0.02 on Friday, hitting $2.62. The company had a trading volume of 610,279 shares, compared to its average volume of 721,829. The company has a market cap of $163.46 million, a PE ratio of -6.89 and a beta of 3.09. Affimed has a 1 year low of $1.40 and a 1 year high of $7.35. The company has a quick ratio of 3.16, a current ratio of 3.17 and a debt-to-equity ratio of 0.03.
Institutional investors and hedge funds have recently modified their holdings of the stock. Stonepine Capital Management LLC purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $2,221,000. Lindbrook Capital LLC purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $38,000. Sigma Planning Corp purchased a new stake in shares of Affimed during the first quarter valued at approximately $46,000. Prescott Group Capital Management L.L.C. increased its position in shares of Affimed by 16.1% during the fourth quarter. Prescott Group Capital Management L.L.C. now owns 190,680 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 26,480 shares during the last quarter. Finally, FDx Advisors Inc. purchased a new stake in shares of Affimed during the fourth quarter valued at approximately $87,000. 37.50% of the stock is owned by institutional investors.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: Different Options Trading Strategies
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.